Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy
详细信息 查看全文
- 作者：Yuichiroh Umemoto (1)
Shinji Okano (1) (2) (3)
Yoshihiro Matsumoto (1)
Hidekazu Nakagawara (1)
Rumi Matono (1)
Shohei Yoshiya (1)
Yo-ichi Yamashita (1)
Tomoharu Yoshizumi (1)
Toru Ikegami (1)
Yuji Soejima (1)
Mamoru Harada (4)
Shinichi Aishima (5)
Yoshinao Oda (5)
Ken Shirabe (1)
Yoshihiko Maehara (1)
1. Department of Surgery and Science ; Graduate School of Medical Sciences ; Kyushu University ; 3-1-1 Maidashi ; Higashi-ku ; Fukuoka ; 812-8582 ; Japan
2. Department of Innovative Applied Oncology ; Graduate School of Medical Sciences ; Kyushu University ; 3-1-1 Maidashi ; Higashi-ku ; Fukuoka ; 812-8582 ; Japan
3. Division of Diagnostic Pathology ; Kyushu University Hospital ; 3-1-1 Maidashi ; Higashi-ku ; Fukuoka ; 812-8582 ; Japan
4. Department of Immunology ; Shimane University Faculty of Medicine ; Izumo ; Shimane ; 693-8501 ; Japan
5. Department of Anatomic Pathology ; Pathological Sciences ; Graduate School of Medical Sciences ; Kyushu University ; 3-1-1 Maidashi ; Higashi-ku ; Fukuoka ; 812-8582 ; Japan - 关键词：Hepatocellular carcinoma ; Cytotoxic T lymphocytes ; Programmed death ; 1 ; Human leukocyte antigens class I ; Prognosis
- 刊名：Journal of Gastroenterology
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：50
- 期：1
- 页码：65-75
- 全文大小：1,740 KB
- 参考文献：1. Shirabe K, Kanematsu T, Matsumata T, et al. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology. 1991;14:802鈥?. CrossRef
2. Herr I, Schemmer P, Buchler MW. On the TRAIL to therapeutic intervention in liver disease. Hepatology. 2007;46:266鈥?4. CrossRef
3. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol: Off J Am Soc Clin Oncol. 2007;25:2586鈥?3. CrossRef
4. Bricard G, Bouzourene H, Martinet O, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol. 2005;174:1709鈥?6. CrossRef
5. Steel JL, Geller DA, Gamblin TC, et al. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2007;25:2397鈥?05. CrossRef
6. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114鈥?5. CrossRef
7. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27:195鈥?01. CrossRef
8. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793鈥?00. CrossRef
9. Shi F, Shi M, Zeng Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer (J International du Cancer). 2011;128:887鈥?6. CrossRef
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med. 2012;366:2443鈥?4. CrossRef
11. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med. 2012;366:2455鈥?5. CrossRef
12. Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206:1327鈥?7. CrossRef
13. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:971鈥?. CrossRef
14. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27:5869鈥?5. CrossRef
15. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104:3360鈥?. CrossRef
16. Garrido F, Cabrera T, Aptsiauri N. 鈥淗ard鈥?and 鈥渟oft鈥?lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer (J International du Cancer). 2010;127:249鈥?6.
17. Mano Y, Aishima S, Fujita N, et al. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiol: J Immunopathol Mol Cell Biol. 2013;80:146鈥?4. CrossRef
18. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252鈥?4. CrossRef
19. Bigelow E, Bever KM, Xu H, et al. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp. 2013;71:e4059.
20. Watson NF, Ramage JM, Madjd Z, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer (J International du Cancer). 2006;118:6鈥?0. CrossRef
21. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836鈥?8. CrossRef
22. Cicinnati VR, Zhang X, Yu Z, et al. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. Int J Cancer (J International du Cancer). 2006;119:2851鈥?0. CrossRef
23. Butterfield LH, Meng WS, Koh A, et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001;166:5300鈥?. CrossRef
24. Matsui M, Machida S, Itani-Yohda T, et al. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma. J Gastroenterol Hepatol. 2002;17:897鈥?07. CrossRef
25. Nishibe M, Une Y, Kobayashi M, et al. HLA class I antigens are possible prognostic factors in hepatocellular carcinoma. Int J Oncol. 1996;8:1243鈥?.
26. Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013;332:3鈥?0. CrossRef - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Gastroenterology
Oncology
Surgical Oncology
Hepatology
Internal Medicine
Colorectal Surgery - 出版者：Springer Japan
- ISSN：1435-5922
文摘
Background Hepatocellular carcinoma (HCC) is one of the most common solid tumors worldwide. Surgery is potentially curative, but high recurrence rates worsen patient prognosis. The interaction between the proteins programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) is an important immune checkpoint. The significance of PD-L1 expression and human leukocyte antigen class I (HLA class I), recognized by CD8 T cells, in the prognosis of patients with HCC remains to be determined. Methods We assessed the levels of PD-L1 and HLA class I expression on HCC samples from 80 patients who had undergone hepatectomy at our institution, and evaluated the correlations between PD-L1 and HLA class I expression and patient prognosis. Results High HLA class I expression was correlated with significantly better recurrence-free survival (RFS), but not overall survival (OS). Multivariate analysis showed that high HLA class I expression was an independent predictor of improved RFS. Low expression of PD-L1 on HCC tended to predict better OS, but the difference was not statistically significant. PD-L1 expression on HCC correlated with the number of CD163-positive macrophages and HLA class I expression with CD3-positive cell infiltration. Univariable and multivariable analyses showed that combined PD-L1 low/HLA class I high expression on HCCs was prognostic for improved OS and RFS. Conclusions PD-L1 status may be a good predictor of prognosis in HCC patients with high HLA class I expression. Novel therapies targeting the PD-L1/PD-1 pathway may improve the prognosis of patients with HCC.